Thromb Haemost 1988; 59(03): 396-399
DOI: 10.1055/s-0038-1647503
Original Article
Schattauer GmbH Stuttgart

HIV-Antibody Seroconversions in Dutch Haemophiliacs Using Heat-Treated and Non Heat-Treated Coagulation Factor Concentrates

Tom F W Wolfs
The Human Retrovirus Laboratory of the Department of Virology and the Pediatric Department, The Netherlands
,
Cees Breederveld
*   The Division of Hemostasis and Thrombosis, Academic Medical Centre of the University of Amsterdam, The Netherlands
,
Willy J A Krone
The Human Retrovirus Laboratory of the Department of Virology and the Pediatric Department, The Netherlands
,
Lia v d Hoek
The Human Retrovirus Laboratory of the Department of Virology and the Pediatric Department, The Netherlands
,
Margreet Bakker
The Human Retrovirus Laboratory of the Department of Virology and the Pediatric Department, The Netherlands
,
Lia Smit
The Human Retrovirus Laboratory of the Department of Virology and the Pediatric Department, The Netherlands
,
Jaap Goudsmit
The Human Retrovirus Laboratory of the Department of Virology and the Pediatric Department, The Netherlands
,
The Dutch haemophilia group › Author Affiliations
Further Information

Publication History

Received 28 July 1986

Accepted after revision 19 January 1988

Publication Date:
26 July 2018 (online)

Summary

A national multicentre study was performed to investigate the effects of donorselection and the use of heat-treated plasma products on seroconversion to HIV in 157 Dutch haemophiliacs. All patients included in the study were seronegative for HIV antibodies in 1983.

Thirteen percent (20/157) seroconverted between 1983 and 1986. Nineteen of 20 seroconversions could be related to the use of non heat-treated products in the year preceding HIV antibody seroconversion. One seroconversion occurred in a person using heat-treated non donor screened product.

Seroconversion rate decreased as a result of the policy to discourage high risk blood donors and no seroconversions were observed following the introduction of donor screening in 1985.

 
  • References

  • 1 Feorino PM, Jaffe HW, Palmer E, Peterman TA, Francis DP, Kalyanaraman VS, Weinstein RA, Stoneburner RL, Alexander WJ, Raevsky C, Getchell JP, Warfield D, Haverkos HW, Kilbourne BW, Nicholson JKA, Curran JW. Transfusion associated acquired immunodeficiency syndrome. N Engl J Med 1985; 312: 1293-1296
  • 2 Goedert JJ, Sarngadharan MG, Eyster ME, Weiss SH, Bodner AJ, Gallo RC, Blattner WA. Antibodies reactive with human T cell leukemia viruses in the serum of haemophiliacs receiving factor VIII concentrate. Blood 1985; 65: 492-495
  • 3 Evatt BL, Gomperts ED, McDougal JS, Ramsey RB. Coincidental appearance of LAV/HTLV-III antibodies in hemophiliacs and the onset of the AIDS epidemic. N Engl J Med 1985; 312: 483-486
  • 4 Melbye M, Biggar RJ, Chermann JC, Montagnier L, Stenbjerg S, Ebbesen P. High prevalence of lymphadenopathy virus (LAV) in European haemophiliacs. Lancet 1984; 2: 40-41
  • 5 Allain JP. Prevalence of HTLV-III/LAV antibodies in patients with hemophilia and in their sexual partners in France. N Engl J Med 1986; 315: 517-518
  • 6 Jones P, Hamilton PJ, Bird G, Fearns M, Oxley A, Tedder R, Cheingsong-Popov R, Codd A. AIDS and haemophilia: morbity and mortality in a well defined population. Br Med J 1985; 291: 695-699
  • 7 Lange JMA, Coutinho RA, Krone WJA, Verdonck LF, Danner SA, Van der Noordaa J, Goudsmit J. Distinct IgG recognition patterns during progression of subclinical and clinical infection with lymphadenopathy associated virus/human T-lymphotropic virus. Br Med J 1986; 292: 228-230
  • 8 Evatt BL, Ramsey RB, Lawrence DN, Zyla LD, Curran JW. The acquried immunodeficiency syndrome in patients with haemophilia. Ann Intern Med 1984; 100: 499-504
  • 9 Van der Meer J, Daenen S, Van Imhoff GW, De Wolf JTM, Halie MR. Absence of seroconversion for HTLV-III in haemophiliacs intensively treated with heat treated factor VIII concentrate. Br Med J 1986; 292: 1049
  • 10 Van den Berg W, Ten Cate JW, Breederveld C, Goudsmit J. Seroconversion to HTLV-III in haemophiliac given heat-treated factor VIII concentrate. Lancet 1986; I: 803
  • 11 Breederveld C, Van den Berg W, Ten Cate JW, Smit L, Goudsmit J. Seroconversion for HIV in patients using heat-treated factor VIII concentrates. II Int Conference on AIDS. 1986 Abstract
  • 12 White 2nd GC, Matthews TJ, Weinhold KJ, Haynes BF, Le Roy Cromartie H, McMillan CW. Bolognesi D R HTLV-III seroconversion associated with heat-treated factor VIII concentrate. Lancet 1986; i: 611-612
  • 13 Tersmette M, De Goede REY, Over J, De Jonge E, Radema H, Lucas CJ, Huisman HG, Miedema F. Thermal inactivation of human immunodeficiency virus in lyophilised blood products evaluated by ID50 titrations. Vox Sang 1986; 51: 239-243
  • 14 CDC. Survey of non-U.S. hemophilia treatment centers for HIV seroconversions following therapy with heattreated factor concentrates. MMWR 1987; 36: 121-124
  • 15 Haemophilia JonesP. AIDS, and no fault compensation. Br Med J 1987; 295: 944-945
  • 16 Eyster ME, Gail MH, Ballard JO, Al-Mondhiry H, Goedert JJ. Natural history of human immunodeficiency virus infections in hemophiliacs: effects of T-cell subsets, platelet counts and age. Ann Intern Med 1987; 107: 1-6
  • 17 CDC. Update: Acquired immunodeficiency syndrome - United States. MMWR 1987; 36: 522-526
  • 18 Ragni MV, Winkelstein A, Kingsley L, Spero JA, Lewis JH. 1986 Update of HIV seroprevalence, seroconversion, AIDS incidence, and immunologic correlates of HIV infection in patients with hemophilia A and B. Blood 1987; 70: 786-790